In support of the U.S. government’s policy to maintain a stockpile to be able to protect every American from smallpox, Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract award by the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) valued at approximately $2 billion over 10 years for the continued supply of ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live) into the U.S. Strategic National Stockpile (SNS). The actual number of ACAM2000 doses to be procured is dependent on certain timing and tiered-pricing terms that are subject to the discretion of ASPR. ACAM2000 vaccine is the only vaccine licensed by the
{iframe}http://www.globenewswire.com/news-release/2019/09/03/1909811/0/en/Emergent-BioSolutions-Awarded-10-Year-HHS-Contract-to-Deliver-ACAM2000-Smallpox-Vaccinia-Vaccine-Live-Into-the-Strategic-National-Stockpile.html{/iframe}